Kidney Disease
161
17-32 of 145
Muthiah Vaduganathan, MD
Carolyn S. P. Lam, MBBS, PhD
Muthiah Vaduganathan, MD, MPH
Jurgen Floege MD
John McMurray, MD
Hiddo L. Heerspink, PhD
John McMurray, MD
Pardeep Jhund, MD, PhD
John McMurray, MD
Hiddo L. Heerspink, PhD
Pardeep Jhund, MD, PhD
John McMurray, MD
Muthiah Vaduganathan, MD
Anne Langsted, MD, PhD
- ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Alexander J. Blood, MD
George L. Bakris, MD
David Bushinsky, MD
Lars Lund, MD
Carolyn Lam, MD, PhD
Maria Luiza Caramori, MD, PhD
Ana Maria Cebrián-Cuenca, MD, PhD
Pam R. Taub, MD, FACC, FASPC
- Kidney DiseaseA multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Antoni Bayés-Genís, MD, PhD
Patrick Rossignol, MD, PhD
Ellie Kelepouris, MD
Stephen J. Greene, MD
- Tackling the risk of hyperkalemia through guideline-recommended heart failure therapyThe key role of RAASi therapy in patients with HF
Shelley Zieroth, MD
- Tackling the risk of hyperkalemia through guideline-recommended heart failure therapyPrescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Aaron Wong, MD
